Profile data is unavailable for this security.
About the company
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
- Revenue in USD (TTM)0.00
- Net income in USD-67.51m
- Incorporated2013
- Employees28.00
- LocationCorbus Pharmaceuticals Holdings Inc500 River Ridge DriveNORWOOD 02062United StatesUSA
- Phone+1 (617) 963-0103
- Websitehttps://www.corbuspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALX Oncology Holdings Inc | 0.00 | -108.01m | 123.07m | 44.00 | -- | 2.71 | -- | -- | -2.01 | -2.01 | 0.00 | 0.8362 | 0.00 | -- | -- | 0.00 | -80.47 | -37.96 | -103.67 | -40.71 | -- | -- | -- | -46,390.86 | -- | -- | 0.2099 | -- | -- | -- | 16.14 | -- | 4.84 | -- |
| Black Diamond Therapeutics Inc | 70.00m | 21.50m | 127.05m | 24.00 | 6.15 | 1.01 | 5.82 | 1.82 | 0.3629 | 0.3629 | 1.23 | 2.22 | 0.4736 | -- | -- | 2,916,667.00 | 14.54 | -42.24 | 16.58 | -46.05 | -- | -- | 30.71 | -- | -- | -- | 0.00 | -- | -- | -- | 15.48 | -- | -- | -- |
| Oramed Pharmaceuticals, Inc. | 2.00m | 43.85m | 127.37m | 13.00 | 3.18 | 0.6429 | 2.90 | 63.68 | 1.01 | 1.01 | 0.0478 | 4.98 | 0.0104 | -- | -- | 153,846.20 | 22.72 | -- | 23.30 | -- | 0.65 | -- | 2,190.40 | -- | -- | -- | 0.00 | -- | -100.00 | -- | -444.98 | -- | -- | -- |
| Jyong Biotech Ltd | 0.00 | -2.95m | 130.01m | 29.00 | -- | -- | -- | -- | -0.0397 | -0.0397 | 0.00 | -0.3027 | 0.00 | -- | -- | 0.00 | -13.35 | -- | -127.41 | -- | -- | -- | -- | -- | -- | -1.96 | 2.79 | -- | -- | -- | 31.39 | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -67.51m | 132.00m | 28.00 | -- | 1.02 | -- | -- | -5.51 | -5.51 | 0.00 | 7.35 | 0.00 | -- | -- | 0.00 | -49.34 | -69.78 | -55.11 | -97.84 | -- | -- | -- | -5,894.85 | -- | -- | 0.00 | -- | -- | -- | 9.85 | -- | -- | -- |
| AVITA Medical Inc | 71.61m | -48.59m | 132.02m | 226.00 | -- | -- | -- | 1.84 | -1.75 | -1.75 | 2.57 | -0.5446 | 1.05 | 1.69 | 6.86 | 316,854.00 | -71.40 | -- | -182.42 | -- | 83.27 | -- | -67.85 | -- | 0.4557 | -8.22 | 1.63 | -- | 11.45 | -- | 21.44 | -- | -- | -- |
| Sangamo Therapeutics Inc | 32.88m | -108.91m | 132.16m | 183.00 | -- | 19.08 | -- | 4.02 | -0.4428 | -0.4428 | 0.1326 | 0.0194 | 0.3289 | -- | 5.97 | 179,644.80 | -108.96 | -30.73 | -204.29 | -37.33 | -- | -- | -331.28 | -147.59 | -- | -- | 0.00 | -- | -67.20 | -10.81 | 62.01 | -- | -58.10 | -- |
| Spero Therapeutics Inc | 40.55m | -43.84m | 132.40m | 32.00 | -- | 4.99 | -- | 3.27 | -0.7949 | -0.7949 | 0.7299 | 0.4705 | 0.4283 | -- | 1.45 | 1,267,156.00 | -46.31 | -35.16 | -69.26 | -42.63 | -- | -- | -108.11 | -111.75 | -- | -- | 0.00 | -- | -53.77 | 21.46 | -400.65 | -- | -- | -- |
| Prelude Therapeutics Inc | 10.50m | -111.77m | 132.65m | 131.00 | -- | 2.04 | -- | 12.63 | -1.47 | -1.47 | 0.1382 | 1.03 | 0.0719 | -- | -- | 80,152.67 | -76.56 | -47.36 | -88.86 | -51.44 | -- | -- | -1,064.50 | -7,615.23 | -- | -- | 0.00 | -- | -- | -- | -4.38 | -- | -0.4137 | -- |
| Vaxart Inc | 148.20m | -50.70m | 133.58m | 105.00 | -- | 4.76 | -- | 0.9013 | -0.2222 | -0.2222 | 0.6495 | 0.1169 | 0.789 | -- | 3.31 | 1,411,467.00 | -26.99 | -49.90 | -80.48 | -58.33 | -- | -- | -34.21 | -875.06 | -- | -31.43 | 0.1161 | -- | 288.94 | 23.82 | 18.82 | -- | -8.21 | -- |
| Unicycive Therapeutics Inc | 0.00 | -33.47m | 133.68m | 22.00 | -- | 3.46 | -- | -- | -2.85 | -2.85 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -74.93 | -188.44 | -101.88 | -723.53 | -- | -- | -- | -6,003.20 | -- | -- | 0.00 | -- | -100.00 | -- | -20.42 | -- | -- | -- |
| Tenaya Therapeutics Inc | 0.00 | -94.26m | 134.92m | 97.00 | -- | 1.25 | -- | -- | -0.7875 | -0.7875 | 0.00 | 0.5061 | 0.00 | -- | -- | 0.00 | -76.77 | -47.44 | -87.21 | -51.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.44 | -- | -18.92 | -- |
| HST Global Inc | 0.00 | -212.63k | 139.70m | 1.00 | -- | 8.48 | -- | -- | -0.0107 | -0.0107 | 0.00 | 0.1167 | 0.00 | -- | -- | -- | -6.87 | -27.80 | -8.09 | -60.19 | -- | -- | -- | -- | -- | -107.48 | 0.0433 | -- | -- | -- | -45.42 | -- | -- | -- |
| Microbot Medical Inc | 0.00 | -13.07m | 142.38m | 21.00 | -- | 1.78 | -- | -- | -0.4513 | -0.4513 | 0.00 | 1.19 | 0.00 | -- | -- | 0.00 | -30.06 | -67.69 | -31.62 | -80.15 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.55 | -- | -35.03 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -58.01m | 144.79m | 33.00 | -- | 7.06 | -- | -- | -0.8938 | -0.8938 | 0.00 | 0.2407 | 0.00 | -- | -- | 0.00 | -68.07 | -48.63 | -75.01 | -52.10 | -- | -- | -- | -1,201.96 | -- | -73.28 | 0.7327 | -- | -100.00 | -- | 30.44 | -- | -39.67 | -- |
| Caribou Biosciences Inc | 9.30m | -157.13m | 144.88m | 147.00 | -- | 1.02 | -- | 15.59 | -1.70 | -1.70 | 0.1004 | 1.52 | 0.0345 | -- | 6.57 | 63,231.29 | -58.27 | -30.69 | -65.59 | -33.30 | -- | -- | -1,690.45 | -562.81 | -- | -- | 0.00 | -- | -71.01 | 11.54 | -46.08 | -- | 40.73 | -- |
Data as of Feb 18 2026. Currency figures normalised to Corbus Pharmaceuticals Holdings Inc's reporting currency: US Dollar USD
48.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cormorant Asset Management LPas of 11 Dec 2025 | 2.34m | 13.36% |
| abrdn, Inc.as of 31 Dec 2025 | 1.32m | 7.53% |
| Octagon Capital Advisors LPas of 31 Dec 2025 | 955.00k | 5.44% |
| Citadel Advisors LLCas of 04 Nov 2025 | 873.31k | 4.98% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 758.47k | 4.32% |
| Prosight Management LPas of 31 Dec 2025 | 683.87k | 3.90% |
| OrbiMed Advisors LLCas of 31 Jan 2026 | 538.60k | 3.07% |
| Stonepine Capital Management LLCas of 31 Dec 2025 | 389.92k | 2.22% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 354.30k | 2.02% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 227.22k | 1.29% |
More ▼
Data from 30 Sep 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
